Shawn Tomasello Buys 22,725 Shares of Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc. (NASDAQ:CABA) Director Shawn Tomasello bought 22,725 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was purchased at an average cost of $2.21 per share, for a total transaction of $50,222.25. Following the completion of the purchase, the director owned 22,725 shares of the company’s stock, valued at $50,222.25. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cabaletta Bio Stock Up 25.6%

Shares of CABA opened at $2.94 on Friday. The stock has a market capitalization of $283.00 million, a P/E ratio of -1.16 and a beta of 3.25. Cabaletta Bio, Inc. has a twelve month low of $0.99 and a twelve month high of $3.67. The firm has a fifty day simple moving average of $2.30 and a two-hundred day simple moving average of $2.12.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. Sell-side analysts expect that Cabaletta Bio, Inc. will post -2.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Cabaletta Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd bought a new position in Cabaletta Bio in the second quarter worth $32,000. CRA Financial Services LLC boosted its holdings in shares of Cabaletta Bio by 36.4% during the 3rd quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after buying an additional 4,000 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Cabaletta Bio in the 3rd quarter worth about $47,000. Comerica Bank increased its stake in shares of Cabaletta Bio by 2,292.1% in the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after acquiring an additional 39,860 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Cabaletta Bio by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 30,629 shares of the company’s stock worth $67,000 after acquiring an additional 9,365 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CABA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Cabaletta Bio in a research note on Friday, October 10th. Cantor Fitzgerald boosted their price objective on shares of Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, Jefferies Financial Group started coverage on shares of Cabaletta Bio in a report on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.25.

More Cabaletta Bio News

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average ~$2.24, increasing his stake to ~1.03M shares — a sizable insider buy from the company’s top executive. Read More.
• Positive Sentiment: Multiple other insiders (director Mark Simon, director Shawn Tomasello, insiders Steve Gavel, Gwendolyn Binder, David J. Chang, and General Counsel Michael Gerard) executed material purchases at ~$2.19–$2.28 per share — broad insider participation that signals management/board conviction. Read More.
• Positive Sentiment: Unusually large options activity: investors bought ~3,428 CABA call options (an ~83% increase vs. average daily call volume), consistent with short‑term bullish speculative interest.
• Positive Sentiment: Company program update coverage: reports say Cabaletta is accelerating its autoimmune CAAR‑T program and is targeting a 2027 FDA filing — a clear development roadmap that could materially de‑risk value if milestones are met. Read More.
• Neutral Sentiment: Analyst coverage remains skewed positive on the longer term (consensus “Moderate Buy” with an average price target well above current levels), but those price targets reflect successful clinical progress and are not guarantees. Read More.
• Neutral Sentiment: Institutional ownership moves reported previously show larger biotech investors increasing stakes — supportive for liquidity, but not an immediate catalyst.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.